Adam Walsh


Canaccord Reiterates Positive View of Vertex Pharmaceuticals Inc. Following Partnership with Parion

Canaccord Genuity analyst Adam Walsh weighed in with an optimistic view on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), reiterating a Buy recommendation on the stock with …

Sarepta Therapeutics Inc (SRPT) Will File NDA; Analysts Have Mixed Ratings

On May 19, Sarepta Therapeutics Inc (NASDAQ:SRPT) announced plans to complete a New Drug Application (NDA) for eteplirsen, Sarepta’s lead product candidate. SRPT …

J.P.Morgan and Canaccord Genuity Are Confident That Vertex Pharmaceuticals Incorporated (VRTX)’s CF Drug Will Receive FDA Approval

On May 12, the FDA advisory committee recommended that the FDA approve Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)’s Orkambi therapy to treat cystic fibrosis. Shares of …

Canaccord Genuity Initiates Buy on Vertex Pharmaceuticals Incorporated; Sees 19% Upside For The Stock

In a research report released Friday, Canaccord Genuity analyst Adam Walsh initiated coverage on shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) with a Buy rating and …

Canaccord Maintains Hold Rating On Sarepta Therapeutics Following 4Q14 Update; Remains On The Sidelines

In a research report published this morning, Canaccord Genuity analyst Adam Walsh maintained a Hold rating on Sarepta Therapeutics Inc (NASDAQ:SRPT) with a $16 price …

UPDATE: We Remain Cautious Near Term On Shares Of Sarepta Therapeutics, Says Canaccord

In a research report sent to investors today, Canaccord Genuity analyst Adam Walsh initiated coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) with a …